Scilex Holding Co (SCLX) shareholders
SCLXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SCLXW
$1.56−0.06 (-3.70%)
Close on Nov 12, 2026Market cap $13.25MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
1M
Shares held, 13F filers
Institutional holders
73
12 new, 10 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 3 sales
Net sold $12.81M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| SCLX Stock Acquisition JV LLC | 30,029,378 | 11.40% | 13D (active) amendment | Jul 3, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SCLX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 301,292 | – | $2.35M | +37,242 | 0.00% |
| BlackRock, Inc. | 109,417 | – | $853.45K | +6,621 | 0.00% |
| Vanguard Fiduciary Trust Co | 45,822 | – | $357.41K | +6,164 | 0.00% |
| Jacobs Levy Equity Management, Inc | 41,163 | – | $321.07K | New | 0.00% |
| State Street Corp | 35,376 | – | $275.93K | – | 0.00% |
| UBS Group AG | 33,376 | – | $260.33K | +26,908 | 0.00% |
| Renaissance Technologies LLC | 33,064 | – | $257.90K | −3,800 | 0.00% |
| Citadel Advisors LLC | 27,497 | – | $214.48K | New | 0.00% |
| Price T Rowe Associates Inc /Md/ | 20,920 | – | $164.00K | New | 0.00% |
| Ashton Thomas Private Wealth, LLC | 18,482 | – | $144.16K | +493 | 0.00% |
| Northern Trust Corp | 15,047 | – | $117.37K | +14 | 0.00% |
| Morgan Stanley | 4,032 | – | $31.45K | −7,941 | 0.00% |
| Vanguard Global Advisers, LLC | 2,937 | – | $22.91K | – | 0.00% |
| Osaic Holdings, Inc. | 2,339 | – | $18.24K | +2,241 | 0.00% |
| Creative Financial Designs Inc /Adv | 1,853 | – | $14.45K | – | 0.00% |
| Jones Financial Companies Lllp | 1,755 | – | $12.48K | +1,003 | 0.00% |
| Royal Bank of Canada | 1,745 | – | $14.00K | +149 | 0.00% |
| Larson Financial Group LLC | 1,419 | – | $11.07K | +1,377 | 0.00% |
| MetLife Investment Management, LLC | 1,090 | – | $8.50K | – | 0.00% |
| Deutsche Bank AG\ | 800 | – | $6.24K | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 73 | 1M | 12 / 12 | 7 / 10 | 0M | 0M |
| Q1 2026 | 73 | 1M | 7 / 8 | 15 / 11 | 0M | 0M |
| Q4 2025 | 82 | 1M | 11 / 12 | 15 / 11 | 1M | 0M |
| Q3 2025 | 83 | 1M | 24 / 13 | 15 / 9 | 0M | 0M |
| Q2 2025 | 68 | 1M | 64 / 1 | 3 / 2 | 1M | 0M |
| Q1 2025 | 6 | 0M | 6 / 0 | 0 / 1 | 0M | 0M |
| Q4 2024 | 1 | 0M | 0 / 0 | 0 / 0 | 0M | 0M |
| Q3 2024 | 1 | 0M | 0 / 0 | 0 / 0 | 0M | 0M |
| Q2 2024 | 1 | 0M | 1 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
22 funds held SCLX in Q1 2026, 93% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of SCLX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 217,510 | – | $1.70M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 76,230 | – | $594.59K | 0.00% | Jun 30, 2026 |
| iShares Micro-Cap ETF | 23,935 | – | $186.69K | 0.01% | Jun 30, 2026 |
| iShares Core S&P Total U.S. Stock Market ETF | 14,742 | – | $114.99K | 0.00% | Jun 30, 2026 |
| T. Rowe Price Extended Equity Market Index Fund | 6,900 | – | $53.82K | 0.00% | Jun 30, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 3,805 | – | $29.68K | 0.00% | Jun 30, 2026 |
| Vanguard Balanced Index Fund | 3,747 | – | $29.23K | 0.00% | Jun 30, 2026 |
| 1290 VT Micro Cap Portfolio | 1,683 | – | $13.13K | 0.01% | Jun 30, 2026 |
| MetLife Russell 2000 Index Portfolio | 627 | – | $4.89K | 0.00% | Jun 30, 2026 |
| Siit Extended Market Index Fund | 344 | – | $3.06K | 0.00% | May 31, 2026 |
| State Street Balanced Index Fund | 120 | – | $936 | 0.00% | Jun 30, 2026 |
| Avantis Total Equity Markets ETF | 80 | – | $712 | 0.00% | May 31, 2026 |
| Dimensional US Core Equity Market ETF | 66 | – | $440 | 0.00% | Jul 31, 2026 |
| LVIP Dimensional U.S. Core Equity 2 Fund | 39 | – | $304 | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Stephen Hoi Ma | CFO, COO and Secretary, Director | 22,840 | Apr 20, 2026 |
| Henry Ji | Exec Chair, CEO and President, Director | 678,135 | Apr 20, 2026 |
| Jaisim Shah | See Remarks, Director | 295,215 | Dec 18, 2024 |
| Jay Chun | Director | 112,511 | Oct 9, 2025 |
| Dorman Followwill | Director | 2,300 | Oct 9, 2025 |
| Yue Alexander Wu | Director | 25,000 | Oct 9, 2025 |
| Stock Acquisition JV LLC SCLX | 10% owner | 958,263 | Jul 7, 2026 |
| Holding Co Scilex | 10% owner | 244,445,260 | Dec 30, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Stock Acquisition JV LLC SCLX 10% owner | Jul 3, 2026 | Other | −500,000 | – | – | 958,263 |
| Holding Co Scilex 10% owner | Dec 30, 2025 | Sale | −9,657,300 | $0.54 | $5.21M | 244,445,260 |
| Holding Co Scilex 10% owner | Dec 29, 2025 | Sale | −7,310,984 | $0.66 | $4.83M | 254,102,560 |
| Holding Co Scilex 10% owner | Dec 26, 2025 | Sale | −3,689,016 | $0.75 | $2.77M | 261,413,544 |
| Stock Acquisition JV LLC SCLX 10% owner | Jan 21, 2025 | Other | −3,250,000 | – | – | 51,039,214 |
| Stock Acquisition JV LLC SCLX 10% owner | Jan 16, 2025 | Other | −779,371 | – | – | 54,289,214 |
| Stock Acquisition JV LLC SCLX 10% owner | Jan 2, 2025 | Other | −5,000,000 | – | – | 55,068,585 |
| Jaisim Shah See Remarks, Director | Dec 18, 2024 | Buy | +30,000 | $0.46 | $13.80K | 139,333 |
| Henry Ji Executive Chairperson, Director | Oct 31, 2024 | Buy | +8,888 | $0.94 | $8.35K | 320,161 |
| Jaisim Shah See Remarks, Director | Oct 29, 2024 | Buy | +32,000 | $0.99 | $31.68K | 109,333 |
| Jay Chun Director | Oct 18, 2024 | Buy | +5,000 | $0.95 | $4.75K | 112,500 |
| Dorman Followwill Director | Oct 18, 2024 | Buy | +1,000 | $0.99 | $990 | 2,300 |
| David Lemus Director | Oct 17, 2024 | Buy | +2,000 | $0.90 | $1.80K | 2,000 |
| Yue Alexander Wu Director | Oct 17, 2024 | Buy | +20,000 | $0.95 | $19.00K | 25,000 |
| Henry Ji Executive Chairperson, Director | Oct 17, 2024 | Buy | +10,000 | $0.97 | $9.70K | 60,070 |
| Stephen Hoi Ma Chief Financial Officer | Oct 16, 2024 | Buy | +6,700 | $0.97 | $6.50K | 22,840 |
| Jaisim Shah See Remarks, Director | Oct 16, 2024 | Buy | +30,000 | $0.99 | $29.70K | 77,333 |
| Dorman Followwill Director | Jun 26, 2024 | Option exercise | +1,000 | $1.37 | $1.37K | 1,300 |
| Jay Chun Director | Jun 20, 2024 | Option exercise | +5,000 | $1.41 | $7.05K | 107,500 |
| Yue Alexander Wu Director | Jun 20, 2024 | Option exercise | +5,000 | $1.41 | $7.05K | 5,000 |
| Jaisim Shah See Remarks, Director | Jun 20, 2024 | Option exercise | +14,000 | $1.73 | $24.22K | 47,333 |
| Stephen Hoi Ma Chief Financial Officer | Jun 20, 2024 | Option exercise | +2,000 | $1.41 | $2.82K | 16,140 |
| Henry Ji Executive Chairperson, Director | Jun 18, 2024 | Option exercise | +6,000 | $1.41 | $8.46K | 311,273 |
| Jaisim Shah See Remarks, Director | Jun 14, 2024 | Option exercise | +33,333 | $1.41 | $47.00K | 33,333 |
| Jaisim Shah See Remarks, Director | May 17, 2024 | Buy | +56,939 | $0.92 | $52.38K | 155,882 |
| Henry Ji Executive Chairperson, Director | May 17, 2024 | Buy | +50,000 | $0.88 | $44.00K | 50,070 |
| Stephen Hoi Ma Chief Financial Officer | May 17, 2024 | Buy | +14,140 | $0.88 | $12.44K | 14,140 |
| Jay Chun Director | May 17, 2024 | Buy | +57,500 | $0.90 | $51.75K | 102,500 |
| Jaisim Shah See Remarks, Director | May 16, 2024 | Buy | +83,061 | $0.84 | $69.77K | 98,943 |
| Sorrento Therapeutics, Inc. 10% owner | Sep 21, 2023 | Sale | −60,068,585 | – | – | 1,917,210 |
| Henry Ji Executive Chairperson, Director | Mar 17, 2023 | Other | +2,730 | $8.60 | $23.48K | 2,730 |
| Sorrento Therapeutics, Inc. 10% owner | Jan 19, 2023 | Other | −73,740,795 | – | – | 61,985,795 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
–
0M shares short
Days to cover
3.4
At 0M shares a day
Change since last report
-10.9%
From 0M shares
Short volume, 20 days
41.1%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Scilex's stock actually held short. Settlement fails (shares not delivered on time) peaked at 2,380 shares on Sep 23, 2026 over the last 90 days.
See a number that looks wrong?